"With over 20 years experience conducting clinical trials for Alzheimer's disease, Mild Cognitive Impairment and Alzheimer's Prevention, Senior Adults Specialty Research is located in Austin, Texas. Our mission is to conduct clinical trials in a manner that expands the options available for medical care, while protecting the rights, dignity, and health of our patients. Our organization is lead by board certified geriatric psychiatrist, Jaron L. Winston, MD and Cliff Whitehead, President."

During the past decade, Senior Adults Specialty Research conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 15 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 11 clinical trials were completed. i.e. 84.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Senior Adults Specialty Research" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Biogen" with 4 trials sponsored, "Brainsway" with 4 trials sponsored, "Athira Pharma" with 2 trials sponsored and "Cassava Sciences, Inc." with 2 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Senior Adults Specialty Research" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "Biogen" with 2 trials as a collaborator, "National Institute on Aging (NIA)" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Banner Alzheimer's Institute" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Senior Adults Specialty Research" are "Alzheimer's Disease" (20 trials), "Alzheimer Disease" (11 trials), "Alzheimers Disease" (2 trials), "Age-Related Cognitive Decline" (1 trials) and "Age-Related Memory Disorders" (1 trials). Many other conditions were trialed in "Senior Adults Specialty Research" in a lesser frequency.

Most popular intervention types in "Senior Adults Specialty Research" are "Drug" (41 trials), "Device" (4 trials), "Biological" (1 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Gantenerumab" (6 trials), "Aducanumab" (3 trials), "CHF 5074 1x" (3 trials) and "CHF 5074 2x" (3 trials). Other intervention names were less common.

The vast majority of trials in "Senior Adults Specialty Research" are 46 trials for "All" genders.

Currently, there are NaN active trials in "Senior Adults Specialty Research". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 21 completed trials in Senior Adults Specialty Research, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Senior Adults Specialty Research, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".